Daiichi Sankyo links with Kitasato for vaccine R&D
This article was originally published in Scrip
Executive Summary
Daiichi Sankyohas struck an alliance with Japan's Kitasato Institute for the R&D, manufacturing and marketing of vaccines for infectious diseases. The tie-up, with a specialised research and commercialisation unit within the institute, will cover both prophylactic and therapeutic vaccines and may extend to collaborations with third parties. Kitasato has developed recombinant technology using the AIK-C measles strain and is also the only academic institute in Japan to operate a vaccine production facility. Daiichi Sankyo has just launched Sanofi-Aventis's paediatric Haemophilus influenzae type B vaccine ActHIB in Japan.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.